Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Aligos Therapeutics Inc (ALGS)

Aligos Therapeutics Inc (ALGS)
33.71 -4.68 (-12.19%) 01/10/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 31.20 -2.51 (-7.45%) 19:26 ET
Quote Overview for Fri, Jan 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
28.10
Day High
37.12
Open 36.09
Previous Close 38.39 38.39
Volume 670,000 670,000
Avg Vol 474,350 474,350
Stochastic %K 40.93% 40.93%
Weighted Alpha +64.16 +64.16
5-Day Change -6.11 (-15.34%) -6.11 (-15.34%)
52-Week Range 6.76 - 46.80 6.76 - 46.80
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 120,948
  • Shares Outstanding, K 3,588
  • Annual Sales, $ 15,530 K
  • Annual Income, $ -87,680 K
  • EBIT $ -95 M
  • EBITDA $ -92 M
  • 60-Month Beta 2.50
  • Price/Sales 38.21
  • Price/Cash Flow N/A
  • Price/Book 2.55

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 105.24%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -2.50
  • Number of Estimates 3
  • High Estimate -1.83
  • Low Estimate -3.67
  • Prior Year -5.50
  • Growth Rate Est. (year over year) +54.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.00 +20.39%
on 12/17/24
Period Open: 30.82
46.80 -27.97%
on 01/06/25
+2.89 (+9.38%)
since 12/10/24
3-Month
6.85 +392.12%
on 10/11/24
Period Open: 6.89
46.80 -27.97%
on 01/06/25
+26.82 (+389.26%)
since 10/10/24
52-Week
6.76 +398.67%
on 10/08/24
Period Open: 18.11
46.80 -27.97%
on 01/06/25
+15.60 (+86.14%)
since 01/10/24

Most Recent Stories

More News
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALGS : 33.71 (-12.19%)
Aligos Therapeutics to Present at Investor Conferences in December

ALGS : 33.71 (-12.19%)
Aligos Therapeutics Reports Positive Clinical Data for ALG-000184 and ALG-055009 at AASLD 2024 Meeting

Aligos Therapeutics reported positive clinical data on ALG-000184 for hepatitis B and ALG-055009 for liver fat reduction.Quiver AI SummaryAligos Therapeutics, Inc. announced positive results from its presentations...

ALGS : 33.71 (-12.19%)
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

ALGS : 33.71 (-12.19%)
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

ALGS : 33.71 (-12.19%)
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

ALGS : 33.71 (-12.19%)
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

ALGS : 33.71 (-12.19%)
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024

ALGS : 33.71 (-12.19%)
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALGS : 33.71 (-12.19%)
Stocks Set to Open Higher as Investors Await Powell Speech, Debt Ceiling Optimism Lifts Sentiment

June S&P 500 futures (ESM23) are up +0.39%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.32% this morning as market participants awaited an update on plans to raise the U.S. debt ceiling while...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
LNC : 30.06 (-2.91%)
PACW : 7.54 (-2.71%)
FSLR : 189.24 (-0.99%)
CS.P.DX : 33.860 (-1.50%)
NGMS : 29.45 (+0.07%)
MMP : 69.00 (+0.67%)
OKE : 101.75 (-1.07%)
ALGS : 33.71 (-12.19%)
DD : 72.70 (-2.35%)
ALB : 86.53 (-0.97%)

Business Summary

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 46.87
2nd Resistance Point 42.00
1st Resistance Point 37.85
Last Price 33.71
1st Support Level 28.83
2nd Support Level 23.96
3rd Support Level 19.81

See More

52-Week High 46.80
Last Price 33.71
Fibonacci 61.8% 31.50
Fibonacci 50% 26.78
Fibonacci 38.2% 22.06
52-Week Low 6.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Trading Volume: The most powerful technical indicator in the world